Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
766.64-
QQQ
712.300.85%
BTC/USD
79062.890.0973%
DIA
535.960.43%
GLD
425.910.18%
TLT
83.13-

Acurx Pharmaceuticals Inc

ACXPNASDAQ
Trade with Public
Trade with Public
$1.40
-0.07-4.76%
At close: Aug 21, 5:00 PM EST
$1.46
-0.01-0.68%
Pre-Market: 8:47 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Acurx Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Acurx Pharmaceuticals (ACXP).

Price Target Range — 9 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingBuy# Analysts1Avg. Consensus PT$17Upside to Avg. PT+1064.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 30, 2025HC Wainwright & Co.Matthew KellerMaintainedBuy$31
Aug 12, 2025HC Wainwright & Co.Matthew KellerPT RaiseBuy$8→$31
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $31 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Raises Price Target to $31

HC Wainwright & Co. analyst Matthew Keller maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and raises the price target from $8 to $31.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Acurx Pharmaceuticals at Buy, Announces Price Target of $8

HC Wainwright & Co. analyst Matthew Kelsey assumes Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy rating and announces Price Target of $8.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $12 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $12 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $12 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved